Ardea (RDEA) Initiates Potenital Gout Treatment Lesinurad Phase 3

Ardea Biosciences, Inc. (Nasdaq: RDEA) has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company's lead product candidate for the chronic treatment of gout. The lesinurad Phase 3 development program is expected to involve approximately 2,000 gout patients at sites around the world. The remaining Phase 3 studies in the program are expected to begin shortly.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• Real and RE/MAX Holdings set Aug. 24 merger closing date
• Firm Capital Apartment REIT posts Q2 loss, plans name change